2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1696

Quantitative Evaluation of Dermal Atrophy by High-Resolution Ultrasonography, Comparing Between Patients Under Long-Term Treatment with Prednisolone or Methylprednisolone
Abstract Number: 911

Race- and Sex-Specific Estimates of 10-, 20-, 30-Year, and Lifetime Risk of Diagnosed Symptomatic Knee Osteoarthritis and the Need for TKR in the US
Abstract Number: 908

Race, Gender and Total Knee Replacement Consideration: The Role of Social Support
Abstract Number: 2138

Racial and Ethnic Disparities in Rheumatoid Arthritis Outcomes in Community-Based U.S. Rheumatology Practices: Results From the Consortium of Rheumatology Researchers of North America Registry
Abstract Number: 795

Racial Differences in Pain Coping Efficacy in Patients with Hip and Knee Osteoarthritis
Abstract Number: 744

Racial Differences in Reported Knee Pain Severity Persist Even After Adjustment for Knee Examination and Radiographic Findings: Data From the Osteoarthritis Initiative
Abstract Number: 2514

Racial/Ethnic Trends in Incidence and Prevalence of Rheumatoid Arthritis in a Large Multi-Ethnic Managed Care Population
Abstract Number: 572

Radiographic Damage in Ankylosing Spondylitis Over 12 Years of Follow-up: A Longitudinal Analysis
Abstract Number: 1012

Radiographic Deformity of the Foot Is Starting From the Early Stage of Rheumatoid Arthritis
Abstract Number: 2631

Radiographic Osteoarthritis Severity Is Associated with an Increased Risk of Developing Knee Pain: Findings From the Osteoarthritis Initiative
Abstract Number: 2486

Radiographic, Clinical and Functional Comparison of Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naïve Patients with Rheumatoid Arthritis
Abstract Number: 1110

Radiologic Progression in Hand Osteoarthritis (OA) Over 2.6 Years – Data From the Sekoia Trial
Abstract Number: 2007

Radiological Peripheral Involvement At Hands, Feet and Hips in Young Adults with Polyarticular Idiopathic Juvenile Arthritis
Abstract Number: 2002

Randomized Clinical Trial in Pediatric Rheumatology: Are Parents and Patients in Equipoise?
Abstract Number: 570

Randomized Controlled Trial of Adalimumab in Patients with Peripheral Spondyloarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].